Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$4.90 USD
-0.10 (-2.00%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FHTX 4.90 -0.10(-2.00%)
Will FHTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Other News for FHTX
FHTX: Upcoming Virtual Meeting Hosted by B. Riley
Foghorn Therapeutics management to meet virtually with B. Riley
Foghorn Therapeutics reports Q2 results
Foghorn Therapeutics Inc (FHTX) Q2 2025 Earnings: EPS of -$0.33 Meets Estimates, Revenue of $7. ...
FHTX Reports Strong Q2 Revenue and Advances Cancer Treatment Pipeline